BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9630457)

  • 1. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
    Hall PD; Kreitman RJ; Willingham MC; Frankel AE
    Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
    Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
    Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
    Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
    Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
    Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
    Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
    Hogge DE; Willman CL; Kreitman RJ; Berger M; Hall PD; Kopecky KJ; McLain C; Tagge EP; Eaves CJ; Frankel AE
    Blood; 1998 Jul; 92(2):589-95. PubMed ID: 9657759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells.
    Kreitman RJ; Pastan I
    Blood; 1997 Jul; 90(1):252-9. PubMed ID: 9207460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
    Frankel AE; Hall PD; Burbage C; Vesely J; Willingham M; Bhalla K; Kreitman RJ
    Blood; 1997 Nov; 90(9):3654-61. PubMed ID: 9345050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF.
    Senchenkov A; Han TY; Wang H; Frankel AE; Kottke TJ; Kaufmann SH; Cabot MC
    Blood; 2001 Sep; 98(6):1927-34. PubMed ID: 11535531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental study of 131I-labeled granulocyte macrophage colony-stimulating factor in SCID mouse-acute myeloid leukemia model].
    Deng YJ; Lou SF; Xu YZ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):33-6. PubMed ID: 17649724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
    Kim CN; Bhalla K; Kreitman RJ; Willingham MC; Hall P; Tagge EP; Jia T; Frankel AE
    Leuk Res; 1999 Jun; 23(6):527-38. PubMed ID: 10374846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.